Charlie Strange to Administration, Inhalation
This is a "connection" page, showing publications Charlie Strange has written about Administration, Inhalation.
Connection Strength
0.720
-
Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD. Int J Chron Obstruct Pulmon Dis. 2019; 14:1377-1388.
Score: 0.157
-
A review of current and developing fixed-dose LABA/LAMA combinations for treating COPD. Expert Opin Pharmacother. 2017 Dec; 18(17):1833-1843.
Score: 0.140
-
Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy. Int J Chron Obstruct Pulmon Dis. 2017; 12:135-140.
Score: 0.132
-
Aclidinium bromide plus formoterol for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2015 Feb; 16(3):427-34.
Score: 0.116
-
Inhaled alpha 1-antitrypsin: gauging patient interest in a new treatment. COPD. 2013 Aug; 10(4):411-5.
Score: 0.102
-
Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments. Int J Chron Obstruct Pulmon Dis. 2015; 10:2055-66.
Score: 0.030
-
Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study. Respir Res. 2015 Apr 23; 16:52.
Score: 0.029
-
Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med. 2003 Jun 17; 138(12):969-73.
Score: 0.013